An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma
Status:
Active, not recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to characterize the safety and efficacy profile of ACP-196
(acalabrutinib) in subjects with relapsed or refractory Mantle Cell Lymphoma (MCL).